On Wednesday, Krystal Biotech announced it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its candidate B-VEC (beremagene geperpavec), intended for the treatment of dystrophic epidermolysis bullosa (DEB).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,